Well you might be saying so long to some of the drug reps you have known for a few years calling on your practice with the news about AstraZeneca so here go a few more jobs in this wonderful “recovering economy” that we have. Banks are recovering, but this doesn’t have any of the same likeness to me.
It looks like Novartis reps see the writing on the wall too as several other pharma company representatives have also challenged the item of working overtime, so it looks like this is somewhat like “get it while you can” action if you will.
Scary thoughts at the link above, how many of us workers does the economy need now that everything is data automated? BD
Novartis‘ 2,500 sales reps should not be paid overtime because they are too rich and work independently like white-collar managers, according to a ruling that is being appealed by the Dept. of Labor. The DOL filed an amicus brief in the case earlier this month. The case is one of many in which pharma sales reps have argued that they are not really salespersons (who are exempt from certain labor laws) and should therefore be paid millions in back-pay for overtime
The big drugmaker faces the same problems as the rest of the industry and so, last week, asked its entire sales force - which numbers between 5,000 and 6,000 in the U.S. - to decide whether to accept a package. However, AstraZeneca prefers to avoid the term buyout and instead instructed its reps to ’self identify’ their interest in walking out the door.